**

Carthera's SonoCloud® Receives EMA Orphan Medicinal Product Designation: A Breakthrough for Treating Cerebral Small Vessel Disease

The European Medicines Agency (EMA) has granted Carthera's innovative SonoCloud® device Orphan Medicinal Product (OMP) designation for the treatment of cerebral small vessel disease (CSVD). This landmark achievement signifies a crucial step forward in addressing this debilitating and often overlooked neurological condition. The designation accelerates the regulatory pathway for SonoCloud®, potentially bringing much-needed relief to patients suffering from CSVD and its devastating consequences. This news is a significant win for Carthera, a leading innovator in the field of focused ultrasound therapy, and a beacon of hope for millions affected by this prevalent, yet under-treated, disease.

What is Cerebral Small Vessel Disease (CSVD)?

CSVD is a common and insidious neurological disorder characterized by damage to the small blood vessels supplying the brain. This damage leads to a range of debilitating symptoms, including:

• Cognitive impairment: Memory loss, difficulty concentrating, and executive dysfunction.
• Motor impairments: Weakness, clumsiness, and gait disturbances.
• Stroke: Increased risk of ischemic stroke and its devastating consequences.
• Dementia: CSVD is a significant contributor to vascular dementia, a prevalent form of dementia.

Currently, limited effective treatment options exist for CSVD, highlighting the urgent need for innovative therapies like SonoCloud®. This underscores the importance of the EMA's OMP designation, which provides Carthera with various advantages, notably streamlined regulatory processes and potential market exclusivity upon approval.

SonoCloud®: A Novel Approach to Treating CSVD

SonoCloud® utilizes focused ultrasound technology to non-invasively treat CSVD. This groundbreaking technology offers a minimally invasive approach, unlike other treatments that often involve surgery or invasive procedures. The device targets specific areas of the brain affected by CSVD, precisely delivering therapeutic ultrasound energy to improve blood flow and reduce damage to the affected vessels.

This targeted approach minimizes potential side effects, making SonoCloud® a potentially safer and more effective alternative to existing treatment options. The technology's precise targeting and non-invasive nature significantly improve the patient experience, reducing recovery time and improving overall quality of life.

The Significance of the EMA's Orphan Medicinal Product Designation

The EMA's OMP designation is a significant validation of SonoCloud®'s potential to treat CSVD. This designation offers several key benefits to Carthera and, ultimately, to patients:

• Accelerated Regulatory Review: The OMP designation streamlines the regulatory approval process, allowing for a faster path to market. This translates to quicker access to this potentially life-changing therapy for patients in need.
• Financial Incentives: The designation may provide access to various financial incentives and grants, supporting the further development and commercialization of SonoCloud®. These resources are crucial for bringing innovative medical devices to market.
• Market Exclusivity: Upon approval, the OMP designation may grant Carthera market exclusivity for SonoCloud® in the treatment of CSVD within the European Union for a specific period. This protection incentivizes investment in research and development.
• Increased Investment: The OMP designation attracts further investment in Carthera, fueling further research and development efforts aimed at improving SonoCloud® and expanding its clinical applications. This is crucial for future innovation and improvement of the device.

Focused Ultrasound Therapy: A Growing Field

Focused ultrasound therapy (FUS) is a rapidly evolving field with the potential to revolutionize the treatment of various neurological conditions. The EMA's endorsement of SonoCloud® strengthens the position of FUS as a powerful therapeutic modality for a range of previously intractable neurological disorders. The success of SonoCloud® will likely further accelerate research and development efforts in this promising area of medicine. Further clinical trials and research may broaden the application of FUS technology for other neurological conditions as well.

The Future of CSVD Treatment

The EMA's OMP designation for SonoCloud® marks a pivotal moment in the fight against CSVD. This milestone is a testament to Carthera’s commitment to innovation and its dedication to improving the lives of patients affected by this devastating condition. The prospect of a non-invasive, effective treatment for CSVD offers renewed hope and a significant improvement in the outlook for millions struggling with this challenging disease.

The next steps for Carthera involve continued clinical trials to further demonstrate the safety and efficacy of SonoCloud®. This involves gathering more robust clinical data to support the subsequent marketing authorization application. The success of these trials will be crucial in paving the way for widespread access to SonoCloud® and its revolutionary approach to CSVD treatment across Europe. The company's dedication to pushing the boundaries of focused ultrasound therapy and their commitment to patient care is undeniably significant in this exciting development. The journey from research to widespread accessibility represents a crucial chapter in the fight against CSVD.

The successful development and commercialization of SonoCloud® could potentially transform the treatment landscape for CSVD, offering a much-needed breakthrough in managing this prevalent and debilitating condition. This advancement highlights the growing importance of innovative medical technology in addressing previously unmet medical needs.